Anti-fluorescein isothiocyanate (FITC) antigen receptors (Anti-FITC BCR/TCR)

B-cell antigen receptors (BCRs) and T-cell receptors (TCRs) recognizing fluorescein isothiocyanate (FITC) epitopes are the primary components of the adaptive immune system targeted in hapten-directed immunotherapy (Leamon and Low, 2001). These receptors are typically induced through vaccination with a hapten-carrier conjugate, such as FITC-labeled Keyhole Limpet Hemocyanin (KLH), which stimulates the production of high-affinity anti-FITC antibodies and T-cells (Amato et al., 2013). Once a robust immune repertoire is established, a bispecific adapter molecule—comprising a targeting ligand such as folate linked to the FITC hapten—is administered to the patient (Amato et al., 2014). This adapter bridges the pre-existing anti-FITC receptors to cells overexpressing the target ligand's receptor, such as folate receptor-alpha on cancer cells or folate receptor-beta on activated macrophages (Paulos et al., 2004). The resulting recruitment of anti-FITC BCRs and TCRs to the disease site triggers potent immune effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and direct T-cell-mediated lysis (ClinicalTrials.gov NCT00492167). This approach, notably developed as the FolateImmune platform, aims to treat various cancers and inflammatory conditions by redirecting the body's immune memory toward specific pathological cells.

Other names

Anti-FITC receptorsAnti-fluorescein receptorsAnti-FITC B-cell and T-cell receptorsAnti-FITC immune repertoireAnti-fluorescein isothiocyanate antibodies

Vaccine-mediated induction of hapten-specific immune receptors followed by adapter-mediated recruitment of those receptors to disease-associated antigens.